Akari Therapeutics Ownership 2024 | Who Owns Akari Therapeutics Now?

Overview ForecastFinancials Chart

Institutional Ownership

0.26%

Insider Ownership

38.21%

Retail Ownership

61.52%

Institutional Holders

2.00

Akari Therapeutics Institutional Shareholders

Institutional Shareholders by % of Total Shares

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
SABBY MANAGEMENT, LLC	-	-	-	-164,026	-100.00%	-	Mar 31, 2024
CORNERSTONE PLANNING GROUP LLC	-	-	-	-5	-100.00%	-	Mar 31, 2024

Akari Therapeutics's largest institutional shareholder is SABBY MANAGEMENT, LLC, holding 0.00% of the company's total share outstanding, currently valued at -. The top 10 institutional shareholders own together 0.00% of the company.

Institutional Shareholders by % of Total Assets

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
SABBY MANAGEMENT, LLC	-	-	-	-164,026	-100.00%	-	Mar 31, 2024
CORNERSTONE PLANNING GROUP LLC	-	-	-	-5	-100.00%	-	Mar 31, 2024

The largest Akari Therapeutics shareholder by % of total assets is SABBY MANAGEMENT, LLC. The company owns 0.00 shares of Akari Therapeutics (AKTX), representing 0.00% of its total assets.

Institutional Buyers

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
CORNERSTONE PLANNING GROUP LLC	-	-	-	-5	-100.00%	-	Mar 31, 2024
SABBY MANAGEMENT, LLC	-	-	-	-164,026	-100.00%	-	Mar 31, 2024

As of Mar 31 2024, Akari Therapeutics's largest institutional buyer is CORNERSTONE PLANNING GROUP LLC. The company purchased -5.00 stocks of AKTX, valued at -.

Institutional Sellers

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
SABBY MANAGEMENT, LLC	-	-	-	-164,026	-100.00%	-	Mar 31, 2024
CORNERSTONE PLANNING GROUP LLC	-	-	-	-5	-100.00%	-	Mar 31, 2024

As of Mar 31 2024, Akari Therapeutics's biggest institutional seller is SABBY MANAGEMENT, LLC. The company sold -0.16M shares of AKTX, valued at -.

Institutional New positions

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date

Institutional Sold Out

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
SABBY MANAGEMENT, LLC	-	-	-	-164,026	-100.00%	-	Mar 31, 2024
CORNERSTONE PLANNING GROUP LLC	-	-	-	-5	-100.00%	-	Mar 31, 2024

Akari Therapeutics's largest sold out institutional shareholder by shares sold is SABBY MANAGEMENT, LLC, sold -0.16M shares, valued at -, as of undefined.

Akari Therapeutics Mutual Fund Holders

Name	% Total Assets	Total Shares	Change Amount	Change %	Date
FIDELITY CONCORD STREET TRUST	0.00%	30,264	-	-	Feb 29, 2024
TRUST FOR PROFESSIONAL MANAGERS	0.00%	24,589	-	-	Feb 29, 2024
FIDELITY CONCORD STREET TRUST	0.00%	1,512	-	-	Feb 29, 2024

Akari Therapeutics's largest mutual fund holder by % of total assets is "FIDELITY CONCORD STREET TRUST", owning 30.26K shares, compromising 0.00% of its total assets.

Akari Therapeutics Institutional Ownership Trends

Institutional Holdings Trend

Date	Holdings	Change %
31 Dec, 23	2	100.00%
30 Sep, 23	1	-93.75%
30 Jun, 23	16	45.45%
31 Mar, 23	11	-26.67%
31 Dec, 22	15	15.38%
30 Sep, 22	13	-7.14%
30 Jun, 22	14	27.27%
31 Mar, 22	11	-
31 Dec, 21	11	-21.43%
30 Sep, 21	14	16.67%
30 Jun, 21	12	-
31 Mar, 21	12	-
31 Dec, 20	12	9.09%
30 Sep, 20	11	-42.11%
30 Jun, 20	19	58.33%
31 Mar, 20	12	-7.69%
31 Dec, 19	13	30.00%
30 Sep, 19	10	11.11%
30 Jun, 19	9	-25.00%
31 Mar, 19	12	71.43%
31 Dec, 18	7	-36.36%
30 Sep, 18	11	10.00%
30 Jun, 18	10	11.11%
31 Mar, 18	9	-52.63%
31 Dec, 17	19	58.33%
30 Sep, 17	12	-20.00%
30 Jun, 17	15	25.00%
31 Mar, 17	12	-25.00%
31 Dec, 16	16	-11.11%
30 Sep, 16	18	-10.00%
30 Jun, 16	20	11.11%
31 Mar, 16	18	-5.26%
31 Dec, 15	19	35.71%
30 Sep, 15	14	-

As of 31 Dec 23, 2 institutions are holding Akari Therapeutics's shares, representing an increase of 100.00% compared to the previous quarter.

Shares Outstanding Trend

Date	Shares Outstanding	Change %
31 Dec, 23	164,031	-7.89%
30 Sep, 23	178,091	-98.23%
30 Jun, 23	10,076,550	-0.44%
31 Mar, 23	10,120,691	13.43%
31 Dec, 22	8,922,318	-11.78%
30 Sep, 22	10,113,790	501.23%
30 Jun, 22	1,682,178	6.75%
31 Mar, 22	1,575,861	9.22%
31 Dec, 21	1,442,780	18.20%
30 Sep, 21	1,220,629	-7.08%
30 Jun, 21	1,313,647	-11.08%
31 Mar, 21	1,477,375	-6.78%
31 Dec, 20	1,584,758	9.47%
30 Sep, 20	1,447,669	-50.24%
30 Jun, 20	2,909,034	26.06%
31 Mar, 20	2,307,615	-2.65%
31 Dec, 19	2,370,463	9.45%
30 Sep, 19	2,165,845	-12.96%
30 Jun, 19	2,488,461	5.36%
31 Mar, 19	2,361,941	13.99%
31 Dec, 18	2,072,086	1.03%
30 Sep, 18	2,050,973	3.25%
30 Jun, 18	1,986,386	-8.92%
31 Mar, 18	2,180,812	-43.75%
31 Dec, 17	3,877,213	57.23%
30 Sep, 17	2,465,922	-21.97%
30 Jun, 17	3,160,176	-6.41%
31 Mar, 17	3,376,632	-14.77%
31 Dec, 16	3,961,951	-1.08%
30 Sep, 16	4,005,099	-4.69%
30 Jun, 16	4,202,288	11.83%
31 Mar, 16	3,757,603	10.28%
31 Dec, 15	3,407,302	28.73%
30 Sep, 15	2,646,851	-

Akari Therapeutics (AKTX) has 164.03K shares outstanding as of 31 Dec 23, down -7.89% compared to the previous quarter.

Institutional Ownership Trend

Date	Ownership %	Change %
31 Dec, 23	0.26%	322.97%
30 Sep, 23	0.29%	0.11%
30 Jun, 23	16.14%	6.14%
31 Mar, 23	16.21%	7.94%
31 Dec, 22	14.29%	4.92%
30 Sep, 22	17.04%	212.12%
30 Jun, 22	2.83%	32.77%
31 Mar, 22	2.94%	30.49%
31 Dec, 21	3.11%	44.99%
30 Sep, 21	2.63%	22.54%
30 Jun, 21	3.41%	23.16%
31 Mar, 21	3.84%	7.71%
31 Dec, 20	7.06%	30.35%
30 Sep, 20	4.82%	5.14%
30 Jun, 20	9.69%	11.52%
31 Mar, 20	9.17%	7.59%
31 Dec, 19	10.99%	9.10%
30 Sep, 19	10.99%	4.58%
30 Jun, 19	15.48%	6.94%
31 Mar, 19	14.94%	8.69%
31 Dec, 18	13.11%	7.28%
30 Sep, 18	13.42%	7.91%
30 Jun, 18	13.02%	6.37%
31 Mar, 18	14.29%	2.01%
31 Dec, 17	26.67%	6.08%
30 Sep, 17	20.94%	2.91%
30 Jun, 17	26.83%	3.26%
31 Mar, 17	28.67%	2.53%
31 Dec, 16	33.64%	2.91%
30 Sep, 16	34.01%	2.67%
30 Jun, 16	35.68%	3.50%
31 Mar, 16	31.91%	3.81%
31 Dec, 15	28.93%	2.52%
30 Sep, 15	33.86%	-

As of 31 Dec 23, Akari Therapeutics is held by 0.26% institutional shareholders, representing a 322.97% growth compared to 30 Sep 23.

Institutional Increased Positions Trend

Date	Increased Positions	Change %
31 Dec, 23	1	-
30 Sep, 23	-	-100.00%
30 Jun, 23	6	100.00%
31 Mar, 23	3	-50.00%
31 Dec, 22	6	-
30 Sep, 22	6	-
30 Jun, 22	6	100.00%
31 Mar, 22	3	-
31 Dec, 21	3	50.00%
30 Sep, 21	2	-66.67%
30 Jun, 21	6	-
31 Mar, 21	6	20.00%
31 Dec, 20	5	25.00%
30 Sep, 20	4	-69.23%
30 Jun, 20	13	85.71%
31 Mar, 20	7	-22.22%
31 Dec, 19	9	12.50%
30 Sep, 19	8	300.00%
30 Jun, 19	2	-71.43%
31 Mar, 19	7	75.00%
31 Dec, 18	4	-20.00%
30 Sep, 18	5	66.67%
30 Jun, 18	3	200.00%
31 Mar, 18	1	-90.91%
31 Dec, 17	11	120.00%
30 Sep, 17	5	-28.57%
30 Jun, 17	7	600.00%
31 Mar, 17	1	-
31 Dec, 16	1	-50.00%
30 Sep, 16	2	-66.67%
30 Jun, 16	6	-
31 Mar, 16	6	-40.00%
31 Dec, 15	10	-28.57%
30 Sep, 15	14	-

1 institutional shareholders have increased their position in AKTX stock as of 31 Dec 23 compared to - in the previous quarter (a 0.00% increase).

Institutional Reduced Positions Trend

Date	Reduced Positions	Change %
31 Dec, 23	1	-
30 Sep, 23	1	-50.00%
30 Jun, 23	2	-
31 Mar, 23	-	-100.00%
31 Dec, 22	3	200.00%
30 Sep, 22	1	-50.00%
30 Jun, 22	2	100.00%
31 Mar, 22	1	-
31 Dec, 21	1	-80.00%
30 Sep, 21	5	-
30 Jun, 21	-	-100.00%
31 Mar, 21	2	100.00%
31 Dec, 20	1	-66.67%
30 Sep, 20	3	-25.00%
30 Jun, 20	4	33.33%
31 Mar, 20	3	200.00%
31 Dec, 19	1	-
30 Sep, 19	1	-66.67%
30 Jun, 19	3	50.00%
31 Mar, 19	2	-
31 Dec, 18	-	-100.00%
30 Sep, 18	3	-
30 Jun, 18	3	-
31 Mar, 18	3	-
31 Dec, 17	3	-25.00%
30 Sep, 17	4	-
30 Jun, 17	4	33.33%
31 Mar, 17	3	-
31 Dec, 16	3	-25.00%
30 Sep, 16	4	-33.33%
30 Jun, 16	6	20.00%
31 Mar, 16	5	-16.67%
31 Dec, 15	6	-
30 Sep, 15	-	-

1 institutional shareholders have reduced their position in AKTX stock as of 31 Dec 23 compared to 1 in the previous quarter (a 0.00% increase).

All Institutional Ownership Trend Data

Date	Holdings	Change %	Shares Outstanding	Change %	Ownership %	Change %	Increased Positions	Change %	Reduced Positions	Change %
31 Dec, 23	2	100.00%	164,031	-7.89%	0.26%	322.97%	1	-	1	-
30 Sep, 23	1	-93.75%	178,091	-98.23%	0.29%	0.11%	-	-100.00%	1	-50.00%
30 Jun, 23	16	45.45%	10,076,550	-0.44%	16.14%	6.14%	6	100.00%	2	-
31 Mar, 23	11	-26.67%	10,120,691	13.43%	16.21%	7.94%	3	-50.00%	-	-100.00%
31 Dec, 22	15	15.38%	8,922,318	-11.78%	14.29%	4.92%	6	-	3	200.00%
30 Sep, 22	13	-7.14%	10,113,790	501.23%	17.04%	212.12%	6	-	1	-50.00%
30 Jun, 22	14	27.27%	1,682,178	6.75%	2.83%	32.77%	6	100.00%	2	100.00%
31 Mar, 22	11	-	1,575,861	9.22%	2.94%	30.49%	3	-	1	-
31 Dec, 21	11	-21.43%	1,442,780	18.20%	3.11%	44.99%	3	50.00%	1	-80.00%
30 Sep, 21	14	16.67%	1,220,629	-7.08%	2.63%	22.54%	2	-66.67%	5	-
30 Jun, 21	12	-	1,313,647	-11.08%	3.41%	23.16%	6	-	-	-100.00%
31 Mar, 21	12	-	1,477,375	-6.78%	3.84%	7.71%	6	20.00%	2	100.00%
31 Dec, 20	12	9.09%	1,584,758	9.47%	7.06%	30.35%	5	25.00%	1	-66.67%
30 Sep, 20	11	-42.11%	1,447,669	-50.24%	4.82%	5.14%	4	-69.23%	3	-25.00%
30 Jun, 20	19	58.33%	2,909,034	26.06%	9.69%	11.52%	13	85.71%	4	33.33%
31 Mar, 20	12	-7.69%	2,307,615	-2.65%	9.17%	7.59%	7	-22.22%	3	200.00%
31 Dec, 19	13	30.00%	2,370,463	9.45%	10.99%	9.10%	9	12.50%	1	-
30 Sep, 19	10	11.11%	2,165,845	-12.96%	10.99%	4.58%	8	300.00%	1	-66.67%
30 Jun, 19	9	-25.00%	2,488,461	5.36%	15.48%	6.94%	2	-71.43%	3	50.00%
31 Mar, 19	12	71.43%	2,361,941	13.99%	14.94%	8.69%	7	75.00%	2	-
31 Dec, 18	7	-36.36%	2,072,086	1.03%	13.11%	7.28%	4	-20.00%	-	-100.00%
30 Sep, 18	11	10.00%	2,050,973	3.25%	13.42%	7.91%	5	66.67%	3	-
30 Jun, 18	10	11.11%	1,986,386	-8.92%	13.02%	6.37%	3	200.00%	3	-
31 Mar, 18	9	-52.63%	2,180,812	-43.75%	14.29%	2.01%	1	-90.91%	3	-
31 Dec, 17	19	58.33%	3,877,213	57.23%	26.67%	6.08%	11	120.00%	3	-25.00%
30 Sep, 17	12	-20.00%	2,465,922	-21.97%	20.94%	2.91%	5	-28.57%	4	-
30 Jun, 17	15	25.00%	3,160,176	-6.41%	26.83%	3.26%	7	600.00%	4	33.33%
31 Mar, 17	12	-25.00%	3,376,632	-14.77%	28.67%	2.53%	1	-	3	-
31 Dec, 16	16	-11.11%	3,961,951	-1.08%	33.64%	2.91%	1	-50.00%	3	-25.00%
30 Sep, 16	18	-10.00%	4,005,099	-4.69%	34.01%	2.67%	2	-66.67%	4	-33.33%
30 Jun, 16	20	11.11%	4,202,288	11.83%	35.68%	3.50%	6	-	6	20.00%
31 Mar, 16	18	-5.26%	3,757,603	10.28%	31.91%	3.81%	6	-40.00%	5	-16.67%
31 Dec, 15	19	35.71%	3,407,302	28.73%	28.93%	2.52%	10	-28.57%	6	-
30 Sep, 15	14	-	2,646,851	-	33.86%	-	14	-	-	-

Akari Therapeutics Insider Shareholders Trades

Open Market Insider Trades

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held	Source

Open Market Insider Buys

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held	Source

Insider Sells

Date	Name	Relation	Role	Buy/Sell	Shares	Price	Value	Shares Held
Jan 02, 2024	Jacques Rachelle Suzanne	director, officer	Chief Executive Officer	Sell	-	-	-	538,457,900
Jan 02, 2024	Jacques Rachelle Suzanne	director, officer	Chief Executive Officer	Sell	29,762,300	$0.01	$369.05K	-
Jan 02, 2024	Jacques Rachelle Suzanne	director, officer	Chief Executive Officer	Sell	152,690,700	-	$244.31K	-
Jan 02, 2024	DICICCO WENDY F	officer	Interim CFO	Sell	5,000,000	-	$8.50K	-

All Insider Owners Trades

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held
Jul 02, 2024	Grissinger Michael	director	-	A-Award	Buy	5,000,000	-	$7.00K	5,000,000
Jul 02, 2024	Patel Samir Rashmikant	director	-	A-Award	Buy	91,396,000	-	-	91,396,000
Jul 02, 2024	Hashad Mohamed Wa'el Ahmed	director	-	A-Award	Buy	5,000,000	-	$7.00K	5,000,000
Jul 02, 2024	WILLIAMS DONALD A	director	-	A-Award	Buy	5,000,000	-	$7.00K	5,000,000
Jul 02, 2024	Prudo-Chlebosz Raymond	director	-	A-Award	Buy	10,000,000	-	$14.00K	10,000,000
Jun 04, 2024	Patel Samir Rashmikant	director	-	A-Award	Buy	1,326,258,000	-	$1.19M	3,411,495,500
Jun 04, 2024	Patel Samir Rashmikant	director	-	A-Award	Buy	1,326,258,000	-	$1.19M	1,326,258,000
Jun 04, 2024	Prudo-Chlebosz Raymond	director	-	A-Award	Buy	1,326,258,000	-	$1.19M	3,657,838,600
Jun 04, 2024	Prudo-Chlebosz Raymond	director	-	A-Award	Buy	1,326,258,000	-	$1.19M	1,326,258,000
May 03, 2024	DICICCO WENDY F	officer	Interim CFO	A-Award	Buy	158,473,915	-	-	158,473,915
Apr 30, 2024	Jacques Rachelle Suzanne	director, officer	Chief Executive Officer	A-Award	Buy	479,569,892	-	-	1,018,027,792
Jan 02, 2024	Jacques Rachelle Suzanne	director, officer	Chief Executive Officer		Sell	-	-	-	538,457,900
Jan 02, 2024	Jacques Rachelle Suzanne	director, officer	Chief Executive Officer		Sell	29,762,300	$0.01	$369.05K	-
Jan 02, 2024	Jacques Rachelle Suzanne	director, officer	Chief Executive Officer		Sell	152,690,700	-	$244.31K	-
Jan 02, 2024	DICICCO WENDY F	officer	Interim CFO		Sell	5,000,000	-	$8.50K	-
Jan 02, 2024	Patel Samir Rashmikant	director	-		Buy	-	-	-	2,085,237,500
Jan 02, 2024	Patel Samir Rashmikant	director	-		Buy	32,500,000	$0.03	$975.00K	-
Jan 02, 2024	Patel Samir Rashmikant	director	-		Buy	5,000,000	$0.02	$110.00K	-
Jan 02, 2024	Patel Samir Rashmikant	director	-		Buy	12,500,000	$0.02	$206.25K	-
Jan 02, 2024	Patel Samir Rashmikant	director	-		Buy	50,000,000	$0.01	$700.00K	-

The last insider sell of Akari Therapeutics's stock was made by Jacques Rachelle Suzanne on Jan 02 2024, selling - shares at - per share (valued at -).

Akari Therapeutics Insider Ownership Trends

All Insider Trades Trend

Date	Buy	Sell	Buy/Sell Ratio
Q3 2024	-	1	-
Q2 2024	11	-	-
Q1 2024	-	10	-
Q4 2023	-	-	-
Q2 2023	-	5	-
Q3 2022	-	1	-
Q2 2022	-	2	-
Q1 2022	-	3	-
Q2 2021	-	2	-
Q2 2020	-	2	-
Q1 2020	-	1	-
Q4 2019	-	1	-
Q3 2019	-	-	-
Q2 2019	-	3	-
Q3 2018	-	1	-
Q2 2016	6	-	-
Q1 2016	1	1	100.00%
Q4 2015	4	-	-
Q3 2015	10	2	500.00%
Q2 2015	-	6	-

0 total buy trades, and 1 total sell trades (buy/sell ratio of 0.00%) were made by Akari Therapeutics's insiders, as of Q3 2024.

Open Market Insider Trades Trend

Date	Buy	Sell	Buy/Sell Ratio
Q3 2024	-	-	-
Q2 2024	-	-	-
Q1 2024	-	-	-
Q4 2023	-	-	-
Q2 2023	-	-	-
Q3 2022	-	-	-
Q2 2022	-	-	-
Q1 2022	-	-	-
Q2 2021	-	-	-
Q2 2020	-	-	-
Q1 2020	-	-	-
Q4 2019	-	-	-
Q3 2019	-	-	-
Q2 2019	-	-	-
Q3 2018	-	-	-
Q2 2016	-	-	-
Q1 2016	-	-	-
Q4 2015	-	-	-
Q3 2015	1	-	-
Q2 2015	-	-	-

As of Q3 2024, Insider owners conducted 0 open market buy trades and 0 open market sell trades of Akari Therapeutics's stocks.

Akari Therapeutics Peer Ownership

Ticker	Company
SLNO	Soleno Therapeutics, Inc.
MGTA	Dianthus Therapeutics, Inc.
ONCR	Oncorus, Inc.
AXLA	Axcella Health Inc.
PULM	Pulmatrix, Inc.
HSTO	Histogen Inc.
CAPR	Capricor Therapeutics, Inc.
DFFN	CervoMed Inc.
SCPS	Scopus BioPharma Inc.
LABP	Landos Biopharma, Inc.
SONN	Sonnet BioTherapeutics Holdings, Inc.
PCSA	Processa Pharmaceuticals, Inc.
ANEB	Anebulo Pharmaceuticals, Inc.
SLRX	Salarius Pharmaceuticals, Inc.

AKTX Ownership FAQ

Who Owns Akari Therapeutics?

Akari Therapeutics is owned by institutional shareholders (0.26%), insiders (38.21%), and public (61.52%). The largest institutional shareholder of Akari Therapeutics is SABBY MANAGEMENT, LLC (0% of total shares) and the top mutual fund owner is FIDELITY CONCORD STREET TRUST (0.00% of total shares).

Who are the major institutional shareholders of Akari Therapeutics?

Akari Therapeutics's major institutional shareholders are SABBY MANAGEMENT, LLC, and CORNERSTONE PLANNING GROUP LLC. The top five shareholders own together 0% of the company's share outstanding.

How many Akari Therapeutics shareholders are there?

As of Dec 2023, there are 2 institutional shareholders of Akari Therapeutics.

What percentage of Akari Therapeutics is owned by SABBY MANAGEMENT, LLC?

SABBY MANAGEMENT, LLC owns 0 shares of Akari Therapeutics, representing 0% of the company's total shares outstanding, valued at $0 (as of Mar 2024).

What percentage of Akari Therapeutics is owned by CORNERSTONE PLANNING GROUP LLC?

As of Mar 2024, CORNERSTONE PLANNING GROUP LLC holds 0 shares of Akari Therapeutics (AKTX), compromising 0% of the company, valued at $0.